LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article: Mumps Vaccines: Current Challenges and Future Prospects.

Almansour, Iman

2020 Volume 11, Page(s) 1999

Abstract: Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the ... ...

Abstract	Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the rise, including in populations with high vaccination coverage. Several epidemiological studies suggest that this infectious virus continues to be a worldwide public health threat. The development and deployment of an improved, prophylactic mumps vaccine that provides long-lasting protection is indeed a priority. The purpose of this review is to provide an immuno-biological perspective on mumps vaccines. Here, we review the virology of mumps, licensed mumps vaccines, and the typical immune responses elicited following mumps vaccination. Furthermore, we discuss the limitations and challenges of the currently licensed mumps vaccines and provide strategies for the development of an improved mumps vaccine.
Language	English
Publishing date	2020-08-20
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2587354-4
ISSN	1664-302X
ISSN	1664-302X
DOI	10.3389/fmicb.2020.01999
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: hCoronavirusesDB: an integrated bioinformatics resource for human coronaviruses.

Almansour, Iman / Boudellioua, Imane

Database : the journal of biological databases and curation

2022 Volume 2022

Abstract: In the twenty-first century, three new human coronaviruses have been identified with known zoonotic origins: severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 was ...

Abstract	In the twenty-first century, three new human coronaviruses have been identified with known zoonotic origins: severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 was identified in November 2019 and is associated with an ongoing pandemic. Molecular surveillance and monitoring studies are essential for containing viral outbreaks, epidemics, and pandemics. In addition, the development and deployment of bioinformatics resources for highly pathogenic human coronaviruses are crucial for understanding the genetic and immunogenic landscape associated with these viruses. Here, we introduce an open-access, integrated resource for SARS-CoV, SARS-CoV-2, and MERS-CoV: the Human Coronaviruses Database and Analysis Resource (hCoronavirusesDB; http://hcoronaviruses.net/), which include nucleotide and protein sequence data obtained for these viruses. The database also offers a user-friendly search interface coupled with bioinformatics analytics and visualization tools. In addition, hCoronavirusesDB contains curated, experimentally validated B cell and T cell epitope data for these viruses. This resource can assist with the molecular surveillance necessary to trace virus circulation and contribute to microevolutionary studies. This application can also serve as a valuable resource for the development of rationally designed pan-coronavirus diagnostic tools, vaccines, and therapeutic agents. Database URL:http://hcoronaviruses.net/.
MeSH term(s)	COVID-19/genetics ; Computational Biology ; Humans ; Middle East Respiratory Syndrome Coronavirus/genetics ; Pandemics ; SARS-CoV-2/genetics
Language	English
Publishing date	2022-03-19
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2496706-3
ISSN	1758-0463 ; 1758-0463
ISSN (online)	1758-0463
ISSN	1758-0463
DOI	10.1093/database/baac017
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.

Elsayed, Mustafa M A / Alfagih, Iman M / Brockbank, Katrina / Aodah, Alhassan H / Ali, Raisuddin / Almansour, Khaled / Shalash, Ahmed O

International journal of pharmaceutics

2024 Volume 655, Page(s) 123966

Abstract: The potential of fine excipient materials to improve the aerodynamic performance of carrier-based dry powder inhalation (DPI) formulations is well acknowledged but not fully elucidated. To improve the understanding of this potential, we studied two fine ... ...

Abstract	The potential of fine excipient materials to improve the aerodynamic performance of carrier-based dry powder inhalation (DPI) formulations is well acknowledged but not fully elucidated. To improve the understanding of this potential, we studied two fine excipient materials: micronized lactose particles and silica microspheres. Inhalation formulations, each composed of a coarse lactose carrier, one of the two fine excipient materials (0.0-15.0 % w/w), and a spray-dried drug (fluticasone propionate) material (1.5 % w/w) were prepared. The physical structure, the flow behavior, the aerosolization behavior, and the aerodynamic performance of the formulations were studied. The two fine excipient materials similarly occupied carrier surface macropores. However, only the micronized lactose particles formed agglomerates and appeared to increase the tensile strength of the formulations. At 2.5 % w/w, the two fine excipient materials similarly improved drug dispersibility, whereas at higher concentrations, the micronized lactose material was more beneficial than the silica microspheres. The findings suggest that fine excipient materials improve drug dispersibility from carrier-based DPI formulations at low concentrations by filling carrier surface macropores and at high concentrations by forming agglomerates and/or enforcing fluidization. The study emphasizes critical attributes of fine excipient materials in carrier-based DPI formulations.
MeSH term(s)	Excipients/chemistry ; Powders/chemistry ; Lactose/chemistry ; Drug Carriers/chemistry ; Dry Powder Inhalers ; Administration, Inhalation ; Surface Properties ; Silicon Dioxide ; Particle Size ; Aerosols/chemistry
Chemical Substances	Excipients ; Powders ; Lactose (J2B2A4N98G) ; Drug Carriers ; Silicon Dioxide (7631-86-9) ; Aerosols
Language	English
Publishing date	2024-03-05
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	428962-6
ISSN	1873-3476 ; 0378-5173
ISSN (online)	1873-3476
ISSN	0378-5173
DOI	10.1016/j.ijpharm.2024.123966
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1409: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.

Almansour, Iman / Macadato, Nabela Calamata / Alshammari, Thamer

Pharmaceuticals (Basel, Switzerland)

2021 Volume 14, Issue 1

Abstract: Since its identification in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in 46 million cases and more than one million deaths ... ...

Abstract	Since its identification in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in 46 million cases and more than one million deaths worldwide, as of 30 October 2020. Limited data exist on the magnitude and durability of antibodies generated by natural infection with SARS-CoV-2 and whether they can provide long-lasting immunity from reinfection. Vaccination has proven the most effective measure for controlling and preventing pandemics and, thus, development of a vaccine against COVID-19 is a top priority. However, the doses required to induce effective, long-lasting antibody responses against SARS-CoV-2 remain undetermined. Here, we present the development of SARS-CoV-2 vaccine candidates encoding the viral spike (S) gene, generated using plasmid (p)DNA technology, and we demonstrate the eliciting of S-specific antibodies in mice after three and four doses. The magnitude of binding and neutralizing antibody responses with three doses of synthetic, codon-optimized, full-length S (S.opt.FL) vaccine is comparable to that generated after four doses, suggesting that three doses are sufficient to elicit robust immune responses. Conversely, four doses of S1.opt pDNA vaccine, containing the S globular head, are required to elicit high levels of neutralizing antibodies. Furthermore, the S.opt.FL pDNA vaccine induces the highest serum levels of interferon (IFN)-γ, a marker for activation of cellular immune responses. Overall, our data show that three doses of S.FL pDNA vaccine elicit potent neutralizing antibody responses, with preclinical data that support the immunogenicity of these COVID-19 vaccine candidates and provide justification for further translational studies.
Language	English
Publishing date	2021-01-06
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2193542-7
ISSN	1424-8247
ISSN	1424-8247
DOI	10.3390/ph14010039
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MMRdb: Measles, mumps, and rubella viruses database and analysis resource.

Almansour, Iman / Alhagri, Mazen

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

2019 Volume 75, Page(s) 103982

Abstract: Measles, mumps, and rubella viruses are well known human pathogens that cause mild to severe illnesses. Despite the existence of MMR vaccines since 1971, outbreaks have been largely documented even in highly vaccinated populations. There is a pressing ... ...

Abstract	Measles, mumps, and rubella viruses are well known human pathogens that cause mild to severe illnesses. Despite the existence of MMR vaccines since 1971, outbreaks have been largely documented even in highly vaccinated populations. There is a pressing need to develop a resource to monitor genetic and antigenic variations among these viruses. Here, we introduced MMRdb, a web central database and analysis resource for measles, mumps, and rubella viruses. Users can search viruses at gene level and obtain sequence information based on gene product, geographic location, year, or host. The MMRdb also catalogs experimentally verified B cells and T cells antigenic epitopes data. A set of computation tools such as multiple sequence alignment, Geo Chart, and sequence similarity BLAST search has been implemented in a user-friendly database. The main features of this database will assist researchers in monitoring genetics and antigenic variations, tracking geographic spread with regards of sequence information, and facilitate the development of diagnostics, vaccines, and immunotherapeutics. Database URL: http://mmrdb.org.
MeSH term(s)	Antigens, Viral/immunology ; Databases, Factual ; Genetic Variation ; Genome, Viral ; Humans ; Measles-Mumps-Rubella Vaccine/genetics ; Measles-Mumps-Rubella Vaccine/immunology ; Morbillivirus/genetics ; Morbillivirus/immunology ; Mumps virus/genetics ; Mumps virus/immunology ; Rubella virus/genetics ; Rubella virus/immunology ; Sequence Analysis, RNA ; User-Computer Interface
Chemical Substances	Antigens, Viral ; Measles-Mumps-Rubella Vaccine
Language	English
Publishing date	2019-07-26
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2037068-4
ISSN	1567-7257 ; 1567-1348
ISSN (online)	1567-7257
ISSN	1567-1348
DOI	10.1016/j.meegid.2019.103982
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5645: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2

Iman Almansour / Nabela Calamata Macadato / Thamer Alshammari

Pharmaceuticals, Vol 14, Iss 1, p

2021 Volume 39

Abstract	Since its identification in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in 46 million cases and more than one million deaths worldwide, as of 30 October 2020. Limited data exist on the magnitude and durability of antibodies generated by natural infection with SARS-CoV-2 and whether they can provide long-lasting immunity from reinfection. Vaccination has proven the most effective measure for controlling and preventing pandemics and, thus, development of a vaccine against COVID-19 is a top priority. However, the doses required to induce effective, long-lasting antibody responses against SARS-CoV-2 remain undetermined. Here, we present the development of SARS-CoV-2 vaccine candidates encoding the viral spike (S) gene, generated using plasmid (p)DNA technology, and we demonstrate the eliciting of S-specific antibodies in mice after three and four doses. The magnitude of binding and neutralizing antibody responses with three doses of synthetic, codon-optimized, full-length S (S.opt.FL) vaccine is comparable to that generated after four doses, suggesting that three doses are sufficient to elicit robust immune responses. Conversely, four doses of S1.opt pDNA vaccine, containing the S globular head, are required to elicit high levels of neutralizing antibodies. Furthermore, the S.opt.FL pDNA vaccine induces the highest serum levels of interferon (IFN)-γ, a marker for activation of cellular immune responses. Overall, our data show that three doses of S.FL pDNA vaccine elicit potent neutralizing antibody responses, with preclinical data that support the immunogenicity of these COVID-19 vaccine candidates and provide justification for further translational studies.
Keywords	vaccine ; SARS-CoV-2 ; virus ; pDNA ; immunity ; antibody ; Medicine ; R ; Pharmacy and materia medica ; RS1-441
Subject code	570
Language	English
Publishing date	2021-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: MMRdb: Measles, mumps, and rubella viruses database and analysis resource

Almansour, Iman / Alhagri, Mazen

Infection, genetics, and evolution. 2019 Nov., v. 75

2019

Abstract	Measles, mumps, and rubella viruses are well known human pathogens that cause mild to severe illnesses. Despite the existence of MMR vaccines since 1971, outbreaks have been largely documented even in highly vaccinated populations. There is a pressing need to develop a resource to monitor genetic and antigenic variations among these viruses. Here, we introduced MMRdb, a web central database and analysis resource for measles, mumps, and rubella viruses. Users can search viruses at gene level and obtain sequence information based on gene product, geographic location, year, or host. The MMRdb also catalogs experimentally verified B cells and T cells antigenic epitopes data. A set of computation tools such as multiple sequence alignment, Geo Chart, and sequence similarity BLAST search has been implemented in a user-friendly database. The main features of this database will assist researchers in monitoring genetics and antigenic variations, tracking geographic spread with regards of sequence information, and facilitate the development of diagnostics, vaccines, and immunotherapeutics. Database URL: http://mmrdb.org
Keywords	databases ; diagnostic techniques ; epitopes ; evolution ; genes ; humans ; immunotherapy ; infection ; measles ; sequence alignment ; sequence homology
Language	English
Dates of publication	2019-11
Publishing place	Elsevier B.V.
Document type	Article
Note	NAL-AP-2-clean
ZDB-ID	2037068-4
ISSN	1567-1348
ISSN	1567-1348
DOI	10.1016/j.meegid.2019.103982
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 5645: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development.

Almansour, Iman / Alfares, Rahaf / Aljofi, Halah

F1000Research

2018 Volume 7, Page(s) 1624

Abstract: Background: ...

Abstract	Background:
MeSH term(s)	Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Epitopes, B-Lymphocyte/immunology ; Humans ; Mice ; Vaccines/administration & dosage ; Vaccines/immunology ; Viral Envelope Proteins/genetics ; Viral Envelope Proteins/immunology ; Zika Virus/immunology ; Zika Virus/isolation & purification ; Zika Virus Infection/immunology ; Zika Virus Infection/therapy ; Zika Virus Infection/virology
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Neutralizing ; Antibodies, Viral ; Epitopes, B-Lymphocyte ; Vaccines ; Viral Envelope Proteins
Language	English
Publishing date	2018-10-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2699932-8
ISSN	2046-1402 ; 2046-1402
ISSN (online)	2046-1402
ISSN	2046-1402
DOI	10.12688/f1000research.16454.2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Large-scale analysis of B-cell epitopes of envelope

Iman Almansour / Rahaf Alfares / Halah Aljofi

F1000Research, Vol

Implications for Zika vaccine and immunotherapeutic development [version 2; peer review: 2 approved]

2019 Volume 7

Abstract: Background: Cases of the re-emergence of Zika virus in 2015 were associated with severe neurologic complications, including Gillien-Barre syndrome in adults and congenital Zika syndrome in newborns. The major structural determinant of immunity to the ... ...

Abstract	Background: Cases of the re-emergence of Zika virus in 2015 were associated with severe neurologic complications, including Gillien-Barre syndrome in adults and congenital Zika syndrome in newborns. The major structural determinant of immunity to the Zika virus is the E protein. Although B-cell epitopes of Zika E protein were recently identified, data regarding epitope variations among Zika strains in pre-epidemic and epidemic periods are lacking. Methods: Here, we conducted systematic bioinformatics analyses of Zika strains isolated between 1968 and 2017. Multiple sequence alignment of E protein as well as B-cell epitopes annotations were performed. In addition, homology-based approach was utilized to construct three-dimensional structures of monomeric E glycoproteins to annotate epitope variations. Lastly, prediction of of N-glycosylation patterns and prediction of protein stability upon mutations were also investigated. Results: Our analyses indicates that epitopes recognized by human mAbs ZIKV-117, ZIKV-15, and ZIKV-19 were highly conserved, suggesting as attractive targets for the development of vaccines and immunotherapeutics directed against diverse Zika strains. In addition, the epitope recognized by ZIKV-E-2A10G6 mAb derived from immunized mice was mostly conserved across Zika strains. Conclusions: Our data provide new insights regarding antigenic similarities between Zika strains circulating worldwide. These data are essential for understanding the impact of evolution on antigenic cross-reactivity between Zika lineages and strains. Further in-vitro analyses are needed to determine how mutationsat predefined epitopes could impact the development of vaccines that can effectively neutralize Zika viruses.
Keywords	Medicine ; R ; Science ; Q
Subject code	570
Language	English
Publishing date	2019-06-01T00:00:00Z
Publisher	F1000 Research Ltd
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Inhalable, Spray-Dried Terbinafine Microparticles for Management of Pulmonary Fungal Infections: Optimization of the Excipient Composition and Selection of an Inhalation Device.

Almansour, Khaled / Alfagih, Iman M / Aodah, Alhassan H / Alheibshy, Fawaz / Ali, Raisuddin / Al Hagbani, Turki / Elsayed, Mustafa M A

Pharmaceutics

2021 Volume 14, Issue 1

Abstract: Terbinafine is a broad-spectrum antifungal agent with therapeutic potential against pulmonary aspergillosis. The main aim of the current study was to investigate the potential of l-leucine, alone and in combination with mannitol, to improve the ... ...

Abstract	Terbinafine is a broad-spectrum antifungal agent with therapeutic potential against pulmonary aspergillosis. The main aim of the current study was to investigate the potential of l-leucine, alone and in combination with mannitol, to improve the performance of spray-dried terbinafine microparticles for inhalation. The study also aimed to investigate the potential of the low resistance Cyclohaler
Language	English
Publishing date	2021-12-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics14010087
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito